Form 4 for RARE Ultragenyx Pharmaceutical Inc.

Accepted 2026-03-03 00:00:00 ET · period of report 2026-03-01 · accession 0001193125-26-089278 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2026-03-03	2026-03-02	RARE	KAKKIS EMIL D	Pres, CEO, Dir	S - Sale	$22.80	-54.4K	659.0K	-8%	-$1.24M
	2026-03-03	2026-03-01	RARE	KAKKIS EMIL D	Pres, CEO, Dir	A - Grant	$0.00	+71.2K	712.9K	+11%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-03-02	S	D	54,404	$22.80	658,994	D	—	—	(F2) Represents shares sold to pay required tax withholdings due to the vesting of RSUs. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range (F4) Includes 490 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on April 30, 2025. (F5) Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
2	Common	Common Stock	2026-03-01	A	A	71,177	$0.00	712,908	D	—	—	(F1) Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metrics.